Cited by 267Psychedelics and Drug StudiesTryptophan and brain disordersNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.

Psychedelics as anti-inflammatory agents

Flanagan, Thomas W., Nichols, Charles D.·2018·International Review of Psychiatry

DOI 10.1080/09540261.2018.1481827

Open this paper in CoChat — free account

Abstract

Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way these compounds are perceived in the medical community and populace at large. One emerging therapeutic area that holds significant promise is their use as anti-inflammatory agents. Activation of 5-HT2A receptors produces potent anti-inflammatory effects in animal models of human inflammatory disorders at sub-behavioural levels. This review discusses the role of the 5-HT2A receptor in the inflammatory response, as well as highlight studies using the 5-HT2A agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] to treat inflammation in cellular and animal models. It also examines potential mechanisms by which 5-HT2A agonists produce their therapeutic effects. Overall, psychedelics regulate inflammatory pathways via novel mechanisms, and may represent a new and exciting treatment strategy for several inflammatory disorders.

Integrity signals

Registry

Crossref · 10.1080/09540261.2018.1481827

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,025
The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
Samson, M., Libert, F., Doranz, B. J., Rucker, J. B., Liesnard, C., Farber, C., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,885
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,805
Pharmacological Reviews
(2024) · Pharmacological Reviews · doi:10.1124/pr · Cited by 2,680
Overview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235

Flagged first, then by citations

Show all 151 references

Research works printed but not linked: 4

Fuxe K., 1975, Postgraduate Medical Journal, 1, 35
Hey P, 1947, Quarterly Journal of Pharmacy and Pharmacology, 20, 129
Jouvet M., 1967, Comptes rendus de l'Académie des Sciences, 264, 360
Meltzer H.Y, 1995, Journal of Clinical Neuroscience, 3, 64

Sorted by citations

Items 101–200 of 267

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 16
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 16
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 21
The allostatic triage model of psychopathology (ATP Model): How reallocation of brain energetic resources under stress elicits psychiatric symptoms
Kelley, D. P., Singleton, S. P., Venable, K. E., Sturm, G., Skovgaard, A., Francis, J., Neylan, T. C., Bradley, E., Woolley, J. D., Picard, M. A., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106419 · Cited by 14
Obsessive-Compulsive Disorder With Rheumatological and Inflammatory Diseases: A Systematic Review
Alsheikh, A. M., & Alsheikh, M. M. (2021) · Cureus · doi:10.7759/cureus.14791 · Cited by 14
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 16
Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”
Bornemann, J., Close, J. B., Ahmad, K., Barba, T., Godfrey, K., Macdonald, L., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1320780 · Cited by 15
Chemistry/structural biology of psychedelic drugs and their receptor(s)
Gumpper, R. H., & Nichols, D. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17361 · Cited by 14
Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats
Ferri, B. G., Novais, C. O., Bonani, R. S., de Barros, W. A., de Fátima, Â., Vilela, F. C., & Giusti‐Paiva, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175926 · Cited by 12
Ayahuasca and its major component harmine promote antinociceptive effects in mouse models of acute and chronic pain
Lauria, P. S. S., Gomes, J. D. M., Abreu, L. S., Santana, R. C., Nunes, V. L. C., Couto, R. D., Colavolpe, P. O., da Silva, M. S., Soares, M. B. P., & Villarreal, C. F. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117710 · Cited by 14
Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 12
Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 15
Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 16
Microdosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 15
The Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 14
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“Other animal studies have proposed that psychedelics may elicit their antidepressant effect through antiinflammatory processes, by inhibiting proinflammatory cytokines TNF-α and IL-6, which have been found to be associated with depression [40].”
Background
IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
Plasma C-reactive protein is lower among marijuana using HIV-negative individuals but not among persons living with HIV
Morgan, E., Hudson, H., D’Aquila, R. T., & Mustanski, B. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-84352-0 · Cited by 11
Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View
Lashgari, N., Khalaji, M., Rana, P., Badrabadi, F., Rahnama, M., Nasoori, H., Roudsari, N. M., Nia, M. M. K., & Shafaroodi, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05097-9 · Cited by 10
Classic psychedelics as therapeutics for psychiatric disorders
Nichols, C. D., & Hendricks, P. S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00049-9 · Cited by 11
Self-citation
Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies
Fissler, P., Vandersmissen, A., Filippi, M., Mavioğlu, R. N., Scholkmann, F., Karabatsiakis, A., & Krähenmann, R. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231164707 · Cited by 10
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Viña, S. M. (2024) · Drug Science Policy and Law · doi:10.1177/20503245231225756 · Cited by 10
From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 12
Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin—A retrospective case studyPreprint
Turkia, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/t6k9b · Cited by 16
Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum
Bove, G. M., & Mokler, D. J. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00230 · Cited by 9
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Classic psychedelics do not affect T cell and monocyte immune responses
Rudin, D., Areesanan, A., Liechti, M. E., & Gründemann, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1042440 · Cited by 11
Emerging medications and pharmacological treatment approaches for substance use disorders
Raymond, J. S., Athanasopoulos, A. G., Badolato, C. J., Doolan, T. M., Scicluna, R. L., Everett, N. A., Bowen, M. T., & James, M. H. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173952 · Cited by 9
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
Qureshi, O., Cowley, J., Pegg, A., Cooper, A. J., Gordon, J., Brady, C., Belli, A., Butterworth, S., Upthegrove, R., Andrews, N., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70138 · Cited by 11
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
Microbiome: The Next Frontier in Psychedelic Renaissance
Kargbo, R. B. (2023) · Journal of Xenobiotics · doi:10.3390/jox13030025 · Cited by 9
Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study
Turkia, M. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100029 · Cited by 8
Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
de Oliveira, D. S., Fontenele, R., Weleff, J., Sofuoglu, M., & Aquino, J. P. D. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2229430 · Cited by 8
Mapping Psilocybin-Assisted Therapies: A Scoping ReviewPreprint
Shore, R., Ioudovski, P., Goldie, C. E., McKeown, S., & Dumont, É. C. (2019) · medRxiv · doi:10.1101/2019.12.04.19013896 · Cited by 8
Kynurenine pathway dysregulation in major depressive disorder: the convergence of excitotoxicity, neuroinflammation, and oxidative stress
O’Regan, G., Plummer, Z., Christie, B. R., Shultz, S. R., & Allen, J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03717-2 · Cited by 11
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Kovacevich, A., Weleff, J., Claytor, B., & Barnett, B. S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2253538 · Cited by 7
Harnessing psychedelics for stroke recovery: therapeutic potential and mechanisms
Yang, Y., Wang, Y., & Wang, X. (2025) · Brain · doi:10.1093/brain/awaf093 · Cited by 7
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
Kinderlehrer, D. A. (2023) · International Medical Case Reports Journal · doi:10.2147/imcrj.s395342 · Cited by 7
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy
Belitzky, E., Carvalho, L. V. R., Taylor, M. V., Naranjo-Ortiz, C., Baum, L. V. M., Fiellin, D. A., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70586 · Cited by 6
LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice
Robinson, G. I., Gerasymchuk, M., Zanikov, T., Gojani, E. G., Asghari, S., Groves, A., Haselhorst, L., Nandakumar, S., Stahl, C., Cruz, C., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040451 · Cited by 6
Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective
Thuery, G., Sheridan, C., Iusan, P., Brar, G., Ledden, K., Freyne, A., Kelly, J. R., & Harkin, A. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10030 · Cited by 7
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges
Ghaznavi, S., & Richter, S. G. (2025) · Drugs · doi:10.1007/s40265-025-02172-2 · Cited by 10
Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis
Gold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
Adapting psychedelic medicine for headache and chronic pain disorders
Schindler, E. A. D., & Hendricks, P. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2246655 · Cited by 8
Psychedelic Christianity: From evangelical hippies and Roman Catholic intellectuals in the sixties to clergy in a Johns Hopkins clinical trial
McCarthy, B., & Priest, H. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00356 · Cited by 6
Future directions for clinical psilocybin research: The relaxed symptom network.
Lewis-Healey, E., Laukkonen, R., & van Elk, M. (2022) · Psychology & Neuroscience · doi:10.1037/pne0000290 · Cited by 6
Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. The Switch Study Investigators.
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 6
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Kit, A., Conway, K., Makarowski, S., O'Regan, G., Allen, J., Shultz, S. R., Bodnar, T. S., & Christie, B. R. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100732 · Cited by 5
Pilot study of psilocybin in patients with post-treatment lyme disease
Garcia‐Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., & Aucott, J. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38091-9 · Cited by 6
Impact of Psilocybin on Peripheral Cytokine Production
DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher‐Stine, L., & Griffiths, R. R. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0039 · Cited by 6
Psychotomimetic compensation versus sensitization
Brouwer, A., Carhart-Harris, R. L., & Raison, C. L. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1217 · Cited by 7
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
Therapeutic benefit versus epistemic risk: Need for empirical research in psychedelic epistemology
Borkel, L. F., Rojas‐Hernández, J., Hernández, D. J. Q., & Henríquez‐Hernández, L. A. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.05.039 · Cited by 6
The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
Venugopal, K., & Bedri, N. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.420 · Cited by 5
Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteersPreprint
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2022) · medRxiv · doi:10.1101/2022.10.31.22281688 · Cited by 5
Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
Subramanian, S., Reneau, T. R., Perry, D., Chacko, R. V., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J. A., Metcalf, N. V., Lenze, E. J., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05189-0 · Cited by 6
Lifetime classic psychedelic use and headaches: A cross-sectional study
Bjurenfalk, Z., Cosmo, A., Simonsson, O., & Ran, C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251324372 · Cited by 5
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia
Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 5
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease
Tap, S. C., Bostoen, T., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.001 · Cited by 4
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights
Henderson, I., Elsaadany, R., Chan, G., Bajaj, V., Duarte, D., Goodman, S., Grunstein, M., Vadhan, N. P., & Duarte, R. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01321-8 · Cited by 4
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment
Androni, X., Boyd, R. J., Rosenberg, P. B., & Mahairaki, V. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1605051 · Cited by 4
Evaluation of Cordyceps militaris steroids as anti-inflammatory agents to combat the Covid-19 cytokine storm: a bioinformatics and structure-based drug designing approach
Singh, M., Verma, H., Narendra, G., Raju, B., Choudhary, S., Bhandu, P., & Silakari, O. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2245039 · Cited by 5
The current state of ayahuasca research in animal models: A systematic reviewPreprint
Daldegan‐Bueno, D., Simionato, N. M., Favaro, V. M., & Maia, L. O. (2022) · doi:10.31234/osf.io/7s3b8 · Cited by 4
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs
Acero, V. P., Flatt, T. A., Gooch, P. M., Gaughan, S. J., Levin, A. W., & Davis, A. K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2515866 · Cited by 4
Psilocybin-assisted psychotherapy in adults with depression – A literature review
Dorczok, M. C., Mittmann, G., Ettl, T., & Steiner‐Hofbauer, V. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111508 · Cited by 4
The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors
Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 4
Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
Effects of congeners of amphetamine on the human heart
Neumann, J., Dhein, S., Kirchhefer, U., Hofmann, B., & Gergs, U. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02983-2 · Cited by 3
Herpes Simplex Virus-1 Induced Serotonin-Associated Metabolic Pathways Correlate With Severity of Virus- and Inflammation-Associated Ocular Disease
Battaglia, D. M., Sanchez‐Pino, M. D., Nichols, C. D., & Foster, T. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.859866 · Cited by 3
Self-citation
Interval delivery of 5HT2A agonists using multilayered polymer films
Hossain, M., Sulochana, S. P., Heath, K. E., Bari, S. M. I., Brewster, P. R., Barnes, J., Munivar, A., Walker, G. M., Puleo, D. A., & Werfel, T. A. (2023) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37497 · Cited by 3
Neurobiologie und Wirkmodelle zu Psychedelika
Herwig, U., Avram, M., Borgwardt, S., & Aicher, H. (2024) · Nervenheilkunde · doi:10.1055/a-2261-0745 · Cited by 3
Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives
Yasin, B., Mehta, S. M., Tewfik, G., & Bekker, A. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00058 · Cited by 4
Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewPreprint
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574146 · Cited by 3
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome
Mauney, E. E., King, F., Murray, H. B., & Kuo, B. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002149 · Cited by 3
Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation
Bobak, L., Dorney, I., Kovacevich, A., & Barnett, B. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2478097 · Cited by 1
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
Davidson, M., Stanciu, G. D., Rabinowitz, J., Untu, I., Dobrin, R., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2480566 · Cited by 3
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Soylemez, K. K., de Boo, E. M., Susuzlu, A., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4030031 · Cited by 2
Substance abuse and inflammation: consequences beyond the brain
Yang, L., & Wheeler, M. A. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.04.011 · Cited by 2
An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD
Baxter, L., Utulu, N., Utulu, F., Utulu, S., Li, L., Strawbridge, R., Powell, T. R., & Rucker, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106806 · Cited by 2
Unique biological and physiological properties of endogenous N, N-dimethyltryptamine from the perspective of functioning of the nervous system
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2023) · Neuropsychiatria i Neuropsychologia · doi:10.5114/nan.2023.129068 · Cited by 2
Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology
McGovern, H. T., Wellman, N., Hutchinson, B. T., Oestreich, L., Cooper, S., Fonzo, G. A., & Doss, M. K. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07163-z · Cited by 2
Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms
Lin Denise, S. (2020) · Journal of Healthcare · doi:10.36959/569/456 · Cited by 2
LSD induces increased signalling entropy in rats’ prefrontal cortexPreprint
Savino, A., & Nichols, C. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449556 · Cited by 2
Self-citation
Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD—A retrospective case studyPreprint
Turkia, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/wupvy · Cited by 5
Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genesPreprint
Mennenga, S. E., Hanson, T., Semple, M. G., Lifshitz, D., Flores, B., Balducci, J., Harker, S. A., Ford, A., & Lewis, C. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7890051/v1 · Cited by 2
Well-Being
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0009 · Cited by 1
Historical Perspectives and Pharmacodynamic Actions of the Magic Mushroom (Psilocybin) for Future Global Healthcare
Lange, B., Morgan, L., Mattox, C., Pathak, S., Liu, K., Nadar, R. M., ren, J., Jeyabalan, J. B., Moore, T., & Dhanasekaran, M. (2024) · Trends in Medical Research · doi:10.3923/tmr.2024.245.273 · Cited by 1
Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway
Afrooghe, A., Ahmadi, E., Lesani, A., Mehranjani, M. S., Elahi, M. M., Babaei, M., Shayan, M., Shafaroodi, H., Jafari, R. M., Foroumadi, A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04152-5 · Cited by 1
Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats
Inan, S., Morris, P., Rawls, S. M., & Daws, S. E. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000856 · Cited by 1
Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts
Norouzkhani, F., Gojani, E. G., Wang, B., Li, D., Shujat, S., Shrestha, A., Rodriguez‐Juarez, R., Kovalchuk, O., & Kovalchuk, I. (2025) · Biochemistry and Cell Biology · doi:10.1139/bcb-2025-0250 · Cited by 2
Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey
VanderZwaag, B., Robinson, J., Garcia‐Romeu, A., García-Barrera, M. A., Lake, S., & Lucas, P. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111624 · Cited by 1
Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
Shadani, S., Greaves, E., Andrews, Z. B., & Foldi, C. J. (2026) · Psychedelics. · doi:10.61373/pp026a.0003 · Cited by 1
Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action
Kazdan, J., Ladha, K. S., & Husain, M. I. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70238 · Cited by 2
Psychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Introduction
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0001 · Cited by 1
Attention
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0005 · Cited by 1
The unpaved road of ayahuasca, a psychoactive brew, as a treatment for neuropathic pain: A review of mechanistic insights and clinical prospects
dos Santos, B. C., Reis, A. K. G., Nucci, R. A. B., Campos, A. C. P., Martins, D. O., Daldegan‐Bueno, D., & Pagano, R. L. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100087 · Cited by 1

Authors: Flanagan, T. W., & Nichols, C. D.
Affiliations: Louisiana State University Health Sciences Center New Orleans (US)
Corresponding author: Nichols, Charles D.
ORCID: Nichols, Charles D.
Venue: International Review of Psychiatry
Publisher: Informa UK Limited
Published: 2018-07-04
Volume: 30
Issue: 4
Pages: 363-375
ISSN: 0954-0261 (ISSN-L)
1369-1627
DOI: 10.1080/09540261.2018.1481827
OpenAlex: W2886249511
Cited by: 267
References: 151
Citations by year: 2026: 37 · 2025: 46 · 2024: 39 · 2023: 54 · 2022: 38 · 2021: 32 · 2020: 15 · 2019: 5
FWCI: 15.30
Type: journal article
Language: en
Open access: closed
Locations: International Review of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: psychedelics, 5-HT2A receptor agonists, anti-inflammatory activity, serotonin, psilocybin, inflammatory diseases, inflammatory signaling, depression, obsessive-compulsive disorder, addiction
MeSH terms: Amphetamines, Animals, Anti-Inflammatory Agents, Anxiety, Behavior, Animal, Depression, Hallucinogens, Humans, Obsessive-Compulsive Disorder, Psilocybin, Receptor, Serotonin, 5-HT2A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Psychedelics as anti-inflammatory agents

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks